BioCure Technology Inc. Provides Update On Pre-Clinical Trial
July 05, 2018
Vancouver, British Columbia – BioCure Technology Inc. (CSE: CURE, OTCQB; BICTF) (“BioCure” or the “Company”) is pleased to announce that its wholly owned subsidiary BiocurePharm Corporation (“Biocure Korea”), started conducting a pre-clinical trial of its CAR T Cell and expects the trial to be completed by the end of Q3, 2018.
Furthermore the Company has announced that Biocure Korea has successfully developed a GMP (Good Manufacturing Practice) manufacturing of viral vectors as MCB (Master Cell Bank) in Korea and successfully completed the efficacy and toxicity test.
Biocure Korea will also have its bio-toxicity distribution test completed by end of July 2018. In Q4 of 2018, Biocure Korea will be preparing for an IND (Investigational New Drug) submission for approval of clinical trial to both Korean FDA (Food and Drug Administration) and EMA (European Medicines Agency). Moreover, BioCure Korea is seeking a CRO (Contract Research Organization) outside of Korea to support and advance its clinical trial.
About Biocure Technology Inc.
Biocure Technology Inc. is a South Korean-based biopharmaceutical company, specializing in the development and commercialization of CAR-T therapy for ALL(Acute lymphoblastic leukemia) and major biosimilar products. Biocure is in the process of preclinical trials of five major biosimilar products in South Korea, including interferon beta 1b, PEG-filgrastim and ranibizumab, as well as CAR-T-cell therapy. Biocure is also developing a foot and mouth disease vaccine, and, a hair growth production product.
ON BEHALF OF THE BOARD OF DIRECTORS
/s/ “Sang Mok Lee”
CEO and Director
For further information, please contact:
Biocure Technology Inc. Telephone: 604-609-7146
Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.